Assessment of acute antivascular effects of vandetanib with high-resolution dynamic contrast-enhanced computed tomographic imaging in a human colon tumor xenograft model in the nude rat

Neoplasia

Volumn 12, Issue 9, 2010, Pages 697-707

  Tai, Joo Ho ^a,b   Tessier, Jean ^c   Ryan, Anderson J ^c   Hoffman, Lisa ^a   Chen, Xiaogang ^b   Lee, Ting Yim ^a,b,d  

^a ST JOSEPH S HEALTH CENTRE   (Canada)

^b ROBARTS RESEARCH INSTITUTE   (Canada)

^c ASTRAZENECA   (United Kingdom)

^d WESTERN UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

IOHEXOL; POLYSORBATE 80; VANDETANIB; VASCULOTROPIN; ANGIOGENESIS INHIBITOR; CONTRAST MEDIUM; DIAGNOSTIC AGENT; N (4 BROMO 2 FLUOROPHENYL) 6 METHOXY 7 ((1 METHYLPIPERIDIN 4 YL)METHOXY)QUINAZOLIN 4 AMINE; N-(4-BROMO-2-FLUOROPHENYL)-6-METHOXY-7-((1-METHYLPIPERIDIN-4-YL)METHOXY)QUINAZOLIN-4-AMINE; PIPERIDINE DERIVATIVE; QUINAZOLINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER TRANSPLANTATION; COLON CANCER; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DENSITY; DISEASE MODEL; DRUG BLOOD LEVEL; HUMAN; HUMAN CELL; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; MALE; MICROVASCULATURE; NONHUMAN; NUDE RAT; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RAT; TREATMENT OUTCOME; TUMOR BLOOD FLOW; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT; ADENOCARCINOMA; ANIMAL; COLON TUMOR; DRUG SCREENING; IMAGE ENHANCEMENT; KINETICS; METHODOLOGY; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; RADIOGRAPHY; TIME; TUMOR CELL LINE; VASCULARIZATION;

ADENOCARCINOMA; ANGIOGENESIS INHIBITORS; ANIMALS; CELL LINE, TUMOR; COLONIC NEOPLASMS; CONTRAST MEDIA; HUMANS; IMAGE ENHANCEMENT; KINETICS; MALE; NEOVASCULARIZATION, PATHOLOGIC; PIPERIDINES; QUINAZOLINES; RATS; RATS, NUDE; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77956813949     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.10292     Document Type: Article

References (55)

1. Folkman J (1971). Tumor angiogenesis: therapeutic implications. N Engl J Med 285, 1182-1186.
2. Li WW., (2000). Tumor angiogenesis: molecular pathology, therapeutic targeting, and imaging. Acad Radiol 7, 800-811.
3. Carmeliet P (2005). Angiogenesis in life, disease and medicine. Nature 438, 932-936.
4. Kerbel RS (2008). Tumor angiogenesis. N Engl J Med 358, 2039-2049.
5. Hicklin DJ and Ellis LM (2005). Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23, 1011-1027.
6. Folkman J (1995). Seminars inMedicine of the Beth IsraelHospital, Boston. Clinical applications of research on angiogenesis. N Engl J Med 333, 1757-1763.
7. Ryan AJ and Wedge SR (2005). ZD6474-a novel inhibitor of VEGFR and EGFR tyrosine kinase activity. Br J Cancer 92(suppl 1), S6-S13.
8. Wedge SR, Ogilvie DJ, Dukes M, Kendrew J, Chester R, Jackson JA, Boffey SJ, Valentine PJ, Curwen JO, Musgrove HL, et al. (2002). ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 62, 4645-4655.
9. McCarty MF, Wey J, Stoeltzing O, LiuW, Fan F, Bucana C, Mansfield PF, Ryan AJ, and Ellis LM., (2004). ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor with additional activity against epidermal growth factor receptor tyrosine kinase, inhibits orthotopic growth and angiogenesis of gastric cancer. Mol Cancer Ther 3, 1041-1048.
10. Conrad C, Ischenko I, Kohl G, Wiegand U, Guba M, Yezhelyev M, Ryan AJ, Barge A, Geissler EK, Wedge SR, et al. (2007). Antiangiogenic and antitumor activity of a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor ZD6474 in a metastatic human pancreatic tumor model. Anticancer Drugs 18, 569-579.
11. Miller AB, Hoogstraten B, Staquet M, and Winkler A (1981). Reporting results of cancer treatment. Cancer 47, 207-214.
12. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, et al. (2000). New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States,National Cancer Institute of Canada. JNatl Cancer Inst 92, 205-216.
13. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S,Gwyther S,Mooney M, et al. (2009).New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45, 228-247.
14. WeidnerN (1995). Intratumor microvessel density as a prognostic factor in cancer. Am J Pathol 147, 9-19.
15. Weidner N, Semple JP, Welch WR, and Folkman J (1991). Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 324, 1-8.
16. Ushijima C, Tsukamoto S, Yamazaki K, Yoshino I, Sugio K, and Sugimachi K (2001). High vascularity in the peripheral region of non-small cell lung cancer tissue is associated with tumor progression. Lung Cancer 34, 233-241.
17. Miles KA and Griffiths MR (2003). Perfusion CT: a worthwhile enhancement? Br J Radiol 76, 220-231.
18. Goh V, Halligan S, Daley F, Wellsted DM, Guenther T, and Bartram CI (2008). Colorectal tumor vascularity: quantitative assessment with multidetector CT-do tumor perfusion measurements reflect angiogenesis? Radiology 249, 510-517.
19. Sabir A, Schor-Bardach R, Wilcox CJ, Rahmanuddin S, Atkins MB, Kruskal JB, Signoretti S, Raptopoulos VD, and Goldberg SN (2008). Perfusion MDCT enables early detection of therapeutic response to antiangiogenic therapy. AJR Am J Roentgenol 191, 133-139.
20. Galbraith SM, Maxwell RJ, Lodge MA, Tozer GM, Wilson J, Taylor NJ, Stirling JJ, Sena L, Padhani AR, and Rustin GJ (2003). Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging. J Clin Oncol 21, 2831-2842.
21. Drevs J, Siegert P, Medinger M, Mross K, Strecker R, Zirrgiebel U, Harder J, Blum H, Robertson J, Jurgensmeier JM, et al. (2007). Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors. J Clin Oncol 25, 3045-3054.
22. Turkbey B,Kobayashi H, Ogawa M, Bernardo M, and Choyke PL (2009). Imaging of tumor angiogenesis: functional or targeted? AJR Am J Roentgenol 193, 304-313.
23. Lee TY, Purdie TG, and Stewart E (2003). CT imaging of angiogenesis. Q J Nucl Med 47, 171-187.
24. Miles KA, Charnsangavej C, Lee FT, Fishman EK, Horton K, and Lee TY (2000). Application of CT in the investigation of angiogenesis in oncology. Acad Radiol 7, 840-850.
25. Lee T (2002). Functional CT: physiological models. Trends Biotechnol 20, S3-S10.
26. Gandhi D, Hoeffner EG, Carlos RC, Case I, andMukherji SK (2003). Computed tomography perfusion of squamous cell carcinoma of the upper aerodigestive tract. Initial results. J Comput Assist Tomogr 27, 687-693.
27. Sahani DV, Kalva SP, Hamberg LM, Hahn PF, Willett CG, Saini S, Mueller PR, and Lee TY (2005). Assessing tumor perfusion and treatment response in rectalcancer with multisection CT: initial observations. Radiology 234, 785-792.
28. Zhu AX, Holalkere NS, Muzikansky A, Horgan K, and Sahani DV., (2008). Early antiangiogenic activity of bevacizumab evaluated by computed tomography perfusion scan in patients with advanced hepatocellular carcinoma. Oncologist 13, 120-125.
29. Petralia G, Preda L, Giugliano G, Jereczek-Fossa BA, Rocca A, D'Andrea G, Holalkere NS, Chiesa F, and Bellomi M (2009). Perfusion computed tomography for monitoring induction chemotherapy in patients with squamous cell carcinoma of the upper aerodigestive tract: correlation between changes in tumor perfusion and tumor volume. J Comput Assist Tomogr 33, 552-559.
30. Bellomi M, Petralia G, Sonzogni A, Zampino MG, and Rocca A (2007). CT perfusion for the monitoring of neoadjuvant chemotherapy and radiation therapy in rectal carcinoma: initial experience. Radiology 244, 486-493.
31. Saunders MP, Wilson R, Peeters M, Smith R, Godwood A, Oliver S, and Van Cutsem E (2009). Vandetanib with FOLFIRI in patients with advanced colorectal adenocarcinoma: results from an open-label, multicentre phase I study. Cancer Chemother Pharmacol 64, 665-672.
32. Smith NR, JamesNH, Oakley I,Wainwright A, Copley C, Kendrew J,Womersley LM, Jurgensmeier JM, Wedge SR, and Barry ST., (2007). Acute pharmacodynamic and antivascular effects of the vascular endothelial growth factor signaling inhibitor AZD2171 in Calu-6 human lung tumor xenografts. Mol Cancer Ther 6, 2198-2208.
33. de Boer R, Humblet Y, Wolf J, Nogova L, Ruffert K, Milenkova T, Smith R, Godwood A, and Vansteenkiste J (2009). An open-label study of vandetanib with pemetrexed in patients with previously treated non-small-cell lung cancer. Ann Oncol 20, 486-491.
34. Bradley DP, Tessier JL, Checkley D, Kuribayashi H,Waterton JC, Kendrew J, and Wedge SR (2008). Effects of AZD2171 and vandetanib (ZD6474, Zactima) on haemodynamic variables in an SW620 human colon tumour model: an investigation using dynamic contrast-enhanced MRI and the rapid clearance blood pool contrast agent, P792 (gadomelitol). NMR Biomed 21, 42-52.
35. Mross K, Fasol U, Frost A, Benkelmann R, Kuhlmann J, Büchert M, Unger C, BlumH,Hennig J,Milenkova TP, et al. (2009). DCE-MRI assessment of the effect of vandetanib on tumor vasculature in patients with advanced colorectal cancer and liver metastases: a randomized phase I study. J Angiogenes Res 1, 1-12.
36. Sevick EM and Jain RK (1989). Geometric resistance to blood flow in solid tumors perfused ex vivo: effects of tumor size and perfusion pressure. Cancer Res 49, 3506-3512.
37. Gyves JW, Ziessman HA, Ensminger WD, Thrall JH, Niederhuber JE, Keyes JW Jr, and Walker S (1984). Definition of hepatic tumor microcirculation by single photon emission computerized tomography (SPECT). J Nucl Med 25, 972-977.
38. Gee MS, Procopio WN,Makonnen S, Feldman MD, Yeilding NM, and LeeWM (2003). Tumor vessel development and maturation impose limits on the effectiveness of anti-vascular therapy. Am J Pathol 162, 183-193.
39. Jain RK (2003). Molecular regulation of vessel maturation. Nat Med 9, 685-693.
40. Qian CN, Huang D, Wondergem B, and Teh BT (2009). Complexity of tumor vasculature in clear cell renal cell carcinoma. Cancer 115, 2282-2289.
41. Schumann P, Touzani O, Young AR, Morello R, Baron JC, and MacKenzie ET (1998). Evaluation of the ratio of cerebral blood flow to cerebral blood volume as an index of local cerebral perfusion pressure. Brain 121(pt 7), 1369-1379.
42. Jain RK (2005). Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307, 58-62.
43. Kerbel RS (2006). Antiangiogenic therapy: a universal chemosensitization strategy for cancer? Science 312, 1171-1175.
44. Willett CG, Boucher Y, di Tomaso E,Duda DG,Munn LL, Tong RT, Chung DC, Sahani DV, Kalva SP, Kozin SV, et al. (2004). Direct evidence that the VEGFspecific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 10, 145-147.
45. Raatschen HJ, Fu Y, Brasch RC, Pietsch H, Shames DM, and Yeh BM., (2009). In vivo monitoring of angiogenesis inhibitory treatment effects by dynamic contrast-enhanced computed tomography in a xenograft tumor model. Invest Radiol 44, 265-270.
46. Inai T, Mancuso M, Hashizume H, Baffert F, Haskell A, Baluk P, Hu-Lowe DD, Shalinsky DR, Thurston G, Yancopoulos GD, et al. (2004). Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol 165, 35-52.
47. Kan Z, Phongkitkarun S, Kobayashi S, Tang Y, Ellis LM, Lee TY, and Charnsangavej C (2005). Functional CT for quantifying tumor perfusion in antiangiogenic therapy in a rat model. Radiology 237, 151-158.
48. Hlatky L, Hahnfeldt P, and Folkman J (2002). Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us. J Natl Cancer Inst 94, 883-893.
49. Wu W, Onn A, Isobe T, Itasaka S, Langley RR, Shitani T, Shibuya K, Komaki R, Ryan AJ, Fidler IJ, et al. (2007). Targeted therapy of orthotopic human lung cancer by combined vascular endothelial growth factor and epidermal growth factor receptor signaling blockade. Mol Cancer Ther 6, 471-483.
50. Jain RK, Duda DG, Clark JW, and Loeffler JS (2006). Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 3, 24-40.
51. Kerbel RS (2005). Therapeutic implications of intrinsic or induced angiogenic growth factor redundancy in tumors revealed. Cancer Cell 8, 269-271.
52. Naganawa M, Kimura Y, Yano J, Mishina M, Yanagisawa M, Ishii K, Oda K, and Ishiwata K (2008). Robust estimation of the arterial input function for Logan plots using an intersectional searching algorithm and clustering in positron emission tomography for neuroreceptor imaging. Neuroimage 40, 26-34.
53. Guo H, Renaut RA, and Chen K (2007). An input function estimation method for FDG-PET human brain studies. Nucl Med Biol 34, 483-492.
54. Boone JM, Velazquez O, and Cherry SR (2004). Small-animal X-ray dose from micro-CT. Mol Imaging 3, 149-158.
55. Thibault JB, Sauer KD, Bouman CA, and Hsieh J (2007). A three-dimensional statistical approach to improved image quality for multislice helical CT. Med Phys 34, 4526-4544.